NRG Therapeutics, a neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, has closed an oversubscribed £50m (US$67m) Series B financing that will enable the firm to achieve clinical…
UK: NRG Therapeutics announces oversubscribed £50m Series B
…
…






